Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Moolec Science ( (MLEC) ) is now available.
On June 16, 2025, Moolec Science SA held an extraordinary general meeting of shareholders in Buenos Aires, Argentina, where two key proposals were approved. The shareholders ratified the Business Combination Agreement with several partners, including Bioceres Group and Union Group, and endorsed the actions of the board members related to this agreement. This approval signifies a strategic move for Moolec, potentially enhancing its market position and operational capabilities.
The most recent analyst rating on (MLEC) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Moolec Science stock, see the MLEC Stock Forecast page.
Spark’s Take on MLEC Stock
According to Spark, TipRanks’ AI Analyst, MLEC is a Neutral.
The overall score reflects significant financial challenges due to high leverage, negative profitability, and cash flow issues. Mixed technical indicators and a negative P/E ratio further highlight uncertainties in the stock’s potential for growth.
To see Spark’s full report on MLEC stock, click here.
More about Moolec Science
Moolec Science SA is a public limited liability company based in the Cayman Islands, operating in the biotechnology industry. The company focuses on developing innovative solutions by combining plant-based technologies with molecular farming to produce animal proteins.
Average Trading Volume: 7,206
Technical Sentiment Signal: Sell
Current Market Cap: $27.23M
For a thorough assessment of MLEC stock, go to TipRanks’ Stock Analysis page.